Evidence map›Paper›PMID 40129527›Full record

ArticleInternational journal of cardiology. Cardiovascular risk and prevention2025

Lipid-lowering prescription patterns after a non-fatal acute coronary syndrome: A retrospective cohort study.

Cristina Gavina, Daniel Seabra Carvalho, Marta Afonso-Silva, Inês Costa, Ana Sofia Freitas, Mariana Canelas-Pais, Nuno Lourenço-Silva, Tiago Taveira-Gomes, Francisco Araújo

Abstract read
In one paragraph

Article in International journal of cardiology. Cardiovascular risk and prevention, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Cristina GavinaCardiology Department, Hospital Pedro Hispano-Unidade Local de Saúde Matosinhos, Matosinhos, Portugal.
Daniel Seabra CarvalhoCardiology Department, Hospital Pedro Hispano-Unidade Local de Saúde Matosinhos, Matosinhos, Portugal.
Marta Afonso-SilvaReal World Evidence Department, Novartis Farma-Produtos Farmacêuticos SA, Porto Salvo, Portugal.
Inês CostaReal World Evidence Department, Novartis Farma-Produtos Farmacêuticos SA, Porto Salvo, Portugal.
Ana Sofia FreitasMedical Department, Novartis Farma-Produtos Farmacêuticos S.A., Porto Salvo, Portugal.
Mariana Canelas-PaisMTG Research and Development Lab, Porto, Portugal.
Nuno Lourenço-SilvaMTG Research and Development Lab, Porto, Portugal.
Tiago Taveira-GomesDepartment of Community Medicine, Information and Health Decision Sciences (MEDCIDS), Faculty of Medicine, University of Porto, Porto, Portugal.
Francisco AraújoDepartment of Internal Medicine, Hospital Lusíadas, Lisbon, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: After an acute atherosclerotic cardiovascular event, high-intensity lipid-lowering therapy (LLT) is needed to reduce recurrence risk. This study aimed to describe LLT prescription patterns and LDL-C levels change after non-fatal acute coronary syndrome (ACS) events and to determine if the recommended goals for LDL-C levels were achieved. Methods: Retrospective cohort study using electronic health records (EHR) of Unidade Local de Saúde de Matosinhos between 2015 and 2023. Participants were adults aged 40-80 years, with a non-fatal ACS hospitalization between 2016 and 2022 (index date); ≥1 general practice appointment in the three years before ACS; and one-year follow-up post-ACS. Sub-analyses focused on gender, age (<and ≥65 years), and whether patients met LDL-C control (55 mg/dL) at one-year post-ACS. Results: Of 544 patients, 270 (49.6 %) were under 65 years, and 164 (30.1 %) were females. Before the ACS, 71.1 % of men and 56.7 % of women had no previous LLT prescription and younger patients showed poorer LDL-C control (132(IQR 64)mg/dL) than older patients (102(IQR 50)mg/dL). One-year post-ACS, only 11.3 % of males and 8.5 % of females met LDL-C target. The proportion of patients without LLT decreased from 66.7 % at baseline to 13.6 % post-ACS. High-intensity LLT prescriptions increased from 2.4 % to 16.5 %, while moderate-intensity LLT remained predominant (65.8 %). Still, 89.5 % of patients had uncontrolled LDL-C levels. Conclusion: Despite initiating/intensifying LLT, one year after ACS most patients did not achieve LDL-C goals. This indicates a significant gap in guideline implementation in clinical practice.

Indexed as

AtherosclerosisElectronic health recordsHydroxymethylglutaryl-CoA reductase inhibitorsLow-density lipoprotein cholesterol

Identifiers

PMID40129527
PMCPMC11929879

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.